Dietary Supplements

Factors associated with adherence to allocated treatment in the ASCEND trial: a mail-based randomised trial of aspirin and of omega-3 fatty acid supplementation in people with diabetes.

TL;DR

In the ASCEND mail-based randomised trial, women and those with higher levels of frailty, smoking, and vascular risk score had poorer adherence to trial medication, while overall adherence was comparable to less streamlined trials in similar populations.

Key Findings

Overall adherence rates were 47.2% for aspirin/placebo and 57.7% for omega-3 FA/placebo among participants at risk of a serious vascular event.

  • 7,312 (47.2%) participants were fully adherent to aspirin/placebo during the period at risk of a serious vascular event (SVE)
  • 8,937 (57.7%) participants were fully adherent to omega-3 FA/placebo during the period at risk of a SVE
  • The trial included 15,480 adults with diabetes using mail-based remote methods
  • Adherence was estimated from 6-monthly follow-up forms and the supply of study treatment packs
  • A binary adherence variable (full versus less than full adherence) was investigated using logistic regression

Women were significantly less likely to be fully adherent than men for both aspirin and omega-3 FA randomisations.

  • For aspirin randomisation: 2,509 (43.3%) women vs. 4,803 (49.6%) men were fully adherent; OR 0.73; 95% CI: 0.68 to 0.80; P < 0.0001
  • For omega-3 FA randomisation: 3,035 (52.4%) women vs. 5,902 (61.0%) men were fully adherent; OR 0.67; 95% CI: 0.61 to 0.72; P < 0.0001
  • The association between female sex and lower adherence was consistent across both treatment randomisations

Adherence decreased with increasing frailty as measured by the Hospital Frailty Risk Score.

  • A statistically significant trend was observed for both treatment randomisations (trend p-value < 0.0001)
  • Hospital Frailty Risk Score was one of the potential predictors of adherence considered in the logistic regression model
  • The association was present for both aspirin/placebo and omega-3 FA/placebo adherence

Smoking status was associated with lower adherence to allocated treatment.

  • Smoking was significantly associated with lower adherence (p-value < 0.0001) for both treatment randomisations
  • Smoking status at study entry was one of the predictor variables considered in the logistic regression analysis

Higher predicted 5-year vascular risk score was associated with lower adherence to allocated treatment.

  • Vascular risk score was significantly associated with lower adherence (p-value < 0.0001)
  • Predicted 5-year vascular risk was one of the potential predictors considered in the logistic regression model

Greater socioeconomic deprivation as measured by the Townsend index was associated with lower adherence.

  • Deprivation was significantly associated with lower adherence (trend p-value = 0.0211, p = 0.0011)
  • Townsend index was used as the measure of deprivation in the logistic regression model

The large mail-based ASCEND trial achieved adherence comparable to less streamlined trials in similar populations.

  • ASCEND used mail-based remote methods to conduct the trial in 15,480 adults with diabetes
  • The authors state the trial has 'comparable adherence with less streamlined trials in similar populations'
  • The trial assessed two separate randomisations: aspirin versus placebo and omega-3 fatty acid supplementation versus placebo

Have a question about this study?

Citation

Madurasinghe V, Mafham M, Buck G, Bowman L, Armitage J. (2026). Factors associated with adherence to allocated treatment in the ASCEND trial: a mail-based randomised trial of aspirin and of omega-3 fatty acid supplementation in people with diabetes.. Trials. https://doi.org/10.1186/s13063-026-09551-4